US OptionsDetailed Quotes
MRK250103C101000
- 0.01
- -0.05-83.33%
15min DelayClose Jan 3 16:00 ET
0.09High0.01Low
0.05Open0.06Pre Close352 Volume729 Open Interest101.00Strike Price453.00Turnover676.06%IV1.89%PremiumJan 3, 2025Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0278Delta0.0680Gamma9914.00Leverage Ratio-38.9866Theta0.0000Rho276.02Eff Leverage0.0001Vega
Merck & Co Stock Discussion
Sign in to post a comment
It is rumored Keith Gill will make new investments in 2025 potentially in the health care sector, based on the new Trump administration & RFK looking out for the health of Americans. Rumor is Keith is attending a New Years Eve party with a friend who's father take a statin alternative drug called NEXLIZET made by $Esperion Therapeutics (ESPR.US)$
This information comes from a friend of CNBC Jim Cramer who is also statin intolerant an...
This information comes from a friend of CNBC Jim Cramer who is also statin intolerant an...
1
Wall Street closed in a sea of red on Wall Street after the Fed cut interest rates by 25 basis points and projected fewer interest rate cuts for 2025 amid sticky and stubborn inflation. This is the “hawkish cut” that many have talked about.
The Dow Jones has declined for 10 straight days, its worst run of consecutive red days since 1974.
It seems that the last path of the Fed's push to bring inflation down to its 2% target is proving more difficult than many have init...
The Dow Jones has declined for 10 straight days, its worst run of consecutive red days since 1974.
It seems that the last path of the Fed's push to bring inflation down to its 2% target is proving more difficult than many have init...
From YouTube
2
$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
10
2
4
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
14
1
4
Columns These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over.
It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare underperformed.
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...
3
One day after we got an inflation data (CPI) that came in line with expectation, the market received a hotter-than-expected producer price index (PPI) reading for November.
This is probably why the market is retreating a little bit.
That said, I believe the Fed will still proceed with its expected 25 basis point rate cut next week because other inflation data over the past few months are showing that it is trending downwards.
$Vanguard S&P 500 ETF (VOO.US)$ $KraneShares CSI China Internet ETF (KWEB.US)$ $First Republic Bank (FRCB.US)$ $Crude Oil Futures(FEB5) (CLmain.US)$ $Goldman Sachs (GS.US)$ $Citigroup (C.US)$ $ChargePoint (CHPT.US)$ $LivePerson (LPSN.US)$ $Clover Health (CLOV.US)$ $Vanguard Growth ETF (VUG.US)$ $JD.com (JD.US)$ $Baidu (BIDU.US)$ $FuboTV (FUBO.US)$ $Merck & Co (MRK.US)$ $The Trade Desk (TTD.US)$
This is probably why the market is retreating a little bit.
That said, I believe the Fed will still proceed with its expected 25 basis point rate cut next week because other inflation data over the past few months are showing that it is trending downwards.
$Vanguard S&P 500 ETF (VOO.US)$ $KraneShares CSI China Internet ETF (KWEB.US)$ $First Republic Bank (FRCB.US)$ $Crude Oil Futures(FEB5) (CLmain.US)$ $Goldman Sachs (GS.US)$ $Citigroup (C.US)$ $ChargePoint (CHPT.US)$ $LivePerson (LPSN.US)$ $Clover Health (CLOV.US)$ $Vanguard Growth ETF (VUG.US)$ $JD.com (JD.US)$ $Baidu (BIDU.US)$ $FuboTV (FUBO.US)$ $Merck & Co (MRK.US)$ $The Trade Desk (TTD.US)$
From YouTube
8
No comment yet
NoobGirl : bro is this real that roaring kitty gonna come?